{"meta":{"query_hash":"238d4fe56bae","filters":{"venue":"Expert Opinion on Orphan Drugs"},"cohort_total":11,"direct_labels_cover":0,"predictions_cover":11,"exported":11,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/238d4fe56bae","api":"https://metacan.xera.ac/api/v1/cohort?venue=Expert+Opinion+on+Orphan+Drugs"},"results":[{"id":"W1525227301","doi":"10.1517/21678707.2015.1046434","title":"Pathogenic mechanisms and the prospect of gene therapy for choroideremia","year":2015,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Retinal Development and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Spark Therapeutics; National Institutes of Health; Canadian Institutes of Health Research; National Institute for Health and Care Research; Alberta Innovates - Health Solutions; National Eye Institute; Wellcome Trust","keywords":"Choroideremia; Medicine; Genetic enhancement; Bioinformatics; Gene; Genetics; Biology; Ophthalmology","score_opus":0.017600666210098426,"score_gpt":0.27590628969068604,"score_spread":0.2583056234805876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1525227301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9053733,0.061167788,0.016156482,0.005626224,0.0017928015,0.0037060943,0.000043821594,0.00005659991,0.0060769236],"genre_scores_gemma":[0.9869492,0.0062233894,0.004428936,0.0011962993,0.0002487642,0.0002291924,0.00013058037,0.00003246799,0.00056115916],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99933356,0.000043719963,0.0001475256,0.0002174868,0.00012709474,0.00013060126],"domain_scores_gemma":[0.9995984,0.00001822836,0.00007092423,0.00018804017,0.00006936748,0.00005503556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030015723,0.00011865899,0.0001283011,0.000021254502,0.000052018037,0.000013428115,0.00012471857,0.000071174545,0.0000070743718],"category_scores_gemma":[0.000050052004,0.000076433855,0.000070986796,0.00003959793,0.000078523175,0.0000026663542,0.000031525098,0.000027845208,0.0000021434985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006718841,0.00019732023,0.00035731893,0.000017198374,0.00016082419,4.403978e-7,0.003689794,0.000012022613,0.9035402,0.013262173,0.034565058,0.037478805],"study_design_scores_gemma":[0.008896993,0.0009817217,0.00039763688,0.00001724555,0.0000020748348,0.000006138881,0.00091909524,0.00007475848,0.83130264,0.0043140706,0.1528236,0.0002640282],"about_ca_topic_score_codex":0.0000071247273,"about_ca_topic_score_gemma":8.2601815e-7,"teacher_disagreement_score":0.118258536,"about_ca_system_score_codex":0.0000065915515,"about_ca_system_score_gemma":0.000060190665,"threshold_uncertainty_score":0.3116882},"labels":[],"label_agreement":null},{"id":"W2144559222","doi":"10.1517/21678707.2015.1092868","title":"Potential of antisense therapy for facioscapulohumeral muscular dystrophy","year":2015,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Facioscapulohumeral muscular dystrophy; Gene knockdown; Muscular dystrophy; Homeobox; Medicine; Gene; Genetic enhancement; Transcription factor; Genetics; Bioinformatics; Cancer research; Biology","score_opus":0.019367090787216195,"score_gpt":0.29689671679021246,"score_spread":0.27752962600299624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144559222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991954,0.0034402253,0.0024738365,0.00038001454,0.0009354518,0.00037161427,0.00004446604,0.000018050117,0.00038233373],"genre_scores_gemma":[0.9969404,0.0010120771,0.00051021966,0.0006079915,0.00044676298,0.000049006027,0.00030884796,0.000023924262,0.00010077313],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991197,0.00006773102,0.00017680104,0.00030917797,0.0001246817,0.00020193706],"domain_scores_gemma":[0.9994157,0.0000079966685,0.00008121693,0.00030299838,0.00009706571,0.000095054784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010514566,0.00015788151,0.00017048317,0.000042962467,0.000056268516,0.000006805806,0.00015115207,0.00014522861,0.000026531585],"category_scores_gemma":[0.00003151066,0.00013955966,0.00017196006,0.0000432312,0.00009494013,0.000004358692,0.000036916917,0.000043416178,0.000008699543],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026691265,0.0003305718,0.00008073188,0.000010028696,0.00010054495,7.797335e-7,0.00038465307,0.00021146282,0.9556836,0.00037771184,0.029900221,0.010250572],"study_design_scores_gemma":[0.0072930288,0.0036246986,0.0008906567,0.000019658837,0.000003291751,0.0000050746125,0.0007307936,0.00022902657,0.6600736,0.00054393813,0.3261307,0.00045557102],"about_ca_topic_score_codex":0.00001981208,"about_ca_topic_score_gemma":3.6009885e-7,"teacher_disagreement_score":0.29623047,"about_ca_system_score_codex":0.000006017208,"about_ca_system_score_gemma":0.000058590274,"threshold_uncertainty_score":0.56910783},"labels":[],"label_agreement":null},{"id":"W2507172233","doi":"10.1080/21678707.2016.1232649","title":"Applying integrated care systems to rare diseases","year":2016,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.18248556257076873,"score_gpt":0.40905931459993955,"score_spread":0.22657375202917082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507172233","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17749849,0.20274925,0.07062347,0.39293408,0.06185667,0.028325912,0.016092464,0.0036158117,0.04630384],"genre_scores_gemma":[0.97233784,0.0007948583,0.00073339295,0.018361082,0.002135435,0.003138431,0.00020525239,0.00012919848,0.002164487],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958076,0.00029283523,0.0023571504,0.00085257716,0.00016681687,0.00052302255],"domain_scores_gemma":[0.9970714,0.0007174576,0.00084203586,0.00077648496,0.00011753794,0.0004750803],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018916909,0.00031349354,0.00088088587,0.00048465704,0.00025241985,0.0001356443,0.00042254728,0.00015264012,0.0007747642],"category_scores_gemma":[0.00149619,0.00028564097,0.00015367498,0.00026494105,0.000050129125,0.00039466633,0.00007769429,0.00009876453,0.009431784],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017785213,0.0002685732,0.017395627,0.00046542613,0.00016092417,0.0000040026284,0.015855977,0.00022427397,0.00007061812,0.18737513,0.75671476,0.021286856],"study_design_scores_gemma":[0.0009752152,0.00013133277,0.0010325856,0.0006966893,8.3143567e-7,0.000002029284,0.008768849,0.0002558812,0.000046470348,0.00033725478,0.9872578,0.0004950599],"about_ca_topic_score_codex":0.0005529216,"about_ca_topic_score_gemma":0.000009690006,"teacher_disagreement_score":0.7948394,"about_ca_system_score_codex":0.001282553,"about_ca_system_score_gemma":0.00014933263,"threshold_uncertainty_score":0.9999596},"labels":[],"label_agreement":null},{"id":"W2560073692","doi":"10.1080/21678707.2017.1264300","title":"Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials","year":2016,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Biobank; Clinical trial; Intensive care medicine; Expert opinion; Incidence (geometry); Cancer; Pathology; Internal medicine; Bioinformatics","score_opus":0.15673021908089185,"score_gpt":0.4498017616627763,"score_spread":0.29307154258188445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560073692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85954833,0.02825053,0.000036301728,0.106239125,0.0012776484,0.0024034227,0.000051316132,0.000046827154,0.0021464678],"genre_scores_gemma":[0.9630728,0.034750294,0.00008027924,0.0016508813,0.0001921666,0.00014330551,0.0000032454436,0.000009995937,0.00009705844],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983847,0.0005284213,0.00053552137,0.0002672368,0.00014522646,0.00013885948],"domain_scores_gemma":[0.9971124,0.0024082523,0.00014906777,0.00020446374,0.000028144264,0.00009767206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013569682,0.0001227747,0.0006030479,0.000057169455,0.000040743038,0.000009135162,0.000050358183,0.0000851324,0.00033585235],"category_scores_gemma":[0.00039357864,0.000052539533,0.00011735248,0.0000785516,0.00035440986,0.00003232544,0.000030173609,0.00008600663,0.000005747122],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005497708,0.0012045075,0.16777112,0.00003635671,0.0005071778,0.000025483001,0.0028423895,0.000002209704,0.00017090661,0.035659336,0.0073709497,0.7789119],"study_design_scores_gemma":[0.05692434,0.0025280414,0.8971023,0.0008322202,0.000062560466,0.000021457821,0.0011796335,0.00007728237,0.0011357397,0.0017351164,0.03814336,0.0002579447],"about_ca_topic_score_codex":0.00009944119,"about_ca_topic_score_gemma":0.000012654296,"teacher_disagreement_score":0.7786539,"about_ca_system_score_codex":0.000111901856,"about_ca_system_score_gemma":0.0001058048,"threshold_uncertainty_score":0.36773476},"labels":[],"label_agreement":null},{"id":"W2626803060","doi":"10.1080/21678707.2017.1341307","title":"Ultra-orphan drugs: can we afford the price","year":2017,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Orphan drug; Medicine; Pharmacology; Bioinformatics","score_opus":0.24206907623390514,"score_gpt":0.4302075575686553,"score_spread":0.18813848133475017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626803060","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04206407,0.013177197,0.0009295311,0.7910083,0.012595494,0.002737672,0.00062925334,0.0003481347,0.13651034],"genre_scores_gemma":[0.941314,0.0066416054,0.00076398125,0.040245082,0.003824584,0.0005009487,0.000086854656,0.00014486712,0.0064780833],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99488616,0.00035652882,0.0027291367,0.0009766299,0.00025849204,0.0007930477],"domain_scores_gemma":[0.9932664,0.0009808876,0.0029522304,0.0023575893,0.00007999304,0.00036290218],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.008682768,0.00042422436,0.0009768442,0.00027764385,0.0017372229,0.0005298313,0.0015713845,0.00024185385,0.0012797563],"category_scores_gemma":[0.0021046235,0.00041154912,0.00027540373,0.00013568833,0.00026322744,0.0006618402,0.00013447438,0.00035517412,0.0051088617],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012237339,0.0004323912,0.004381773,0.00021251052,0.00024913548,0.0000028071445,0.05749472,0.00006787596,0.000033065364,0.3217311,0.6041787,0.0110935485],"study_design_scores_gemma":[0.0012589609,0.00014039488,0.0023205488,0.0002030197,0.0000015906243,0.0000045932898,0.0046032746,0.00061199354,0.00023023896,0.008344626,0.98167294,0.00060781447],"about_ca_topic_score_codex":0.002014376,"about_ca_topic_score_gemma":0.00007711425,"teacher_disagreement_score":0.8992499,"about_ca_system_score_codex":0.0006469619,"about_ca_system_score_gemma":0.00020528989,"threshold_uncertainty_score":0.99983364},"labels":[],"label_agreement":null},{"id":"W2737330112","doi":"10.1080/21678707.2017.1359086","title":"Morbidity and mortality associated with Farber disease and prospects for therapy","year":2017,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Children's Hospital","funders":"National Institutes of Health","keywords":"Medicine; Disease; Intensive care medicine; Adult-onset Still's disease; Internal medicine","score_opus":0.06523544874345108,"score_gpt":0.37822828517479723,"score_spread":0.3129928364313461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737330112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99165684,0.0028991352,0.00001616471,0.003244304,0.000121606034,0.0013320232,0.000033773285,0.000054655266,0.0006415275],"genre_scores_gemma":[0.9966445,0.0018374042,0.00005866026,0.0004379053,0.0001870286,0.00020720401,0.000046364574,0.000034777797,0.0005461726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987864,0.00003769128,0.000117363685,0.0004062926,0.00038039792,0.00027189098],"domain_scores_gemma":[0.9988958,0.00008912307,0.000094532945,0.000480457,0.00012008095,0.00031997685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002127587,0.00017523866,0.00025414865,0.00004631277,0.0004302537,0.00011360028,0.00010598011,0.00006904555,0.00005243817],"category_scores_gemma":[0.000495511,0.00012429926,0.000045963247,0.000039389655,0.00024518408,0.00014567691,0.000056903908,0.0001150417,0.0000030814774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058237463,0.001634668,0.9409789,0.00014653138,0.000602288,0.00007108514,0.0029567415,5.2065405e-7,0.0018084688,0.0015962868,0.010122136,0.034258656],"study_design_scores_gemma":[0.006774156,0.0007543717,0.9797542,0.00017333959,0.0000075408416,0.0000027820663,0.00011361306,0.00026859445,0.0013205545,0.00028320056,0.010338847,0.00020880501],"about_ca_topic_score_codex":0.00018065432,"about_ca_topic_score_gemma":0.00001733624,"teacher_disagreement_score":0.038775325,"about_ca_system_score_codex":0.000058275466,"about_ca_system_score_gemma":0.00008670605,"threshold_uncertainty_score":0.50687766},"labels":[],"label_agreement":null},{"id":"W2895884786","doi":"10.1080/21678707.2018.1536542","title":"Advances in emerging therapeutics for oculopharyngeal muscular dystrophy","year":2018,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oculopharyngeal muscular dystrophy; Muscular dystrophy; Internal medicine","score_opus":0.03677599223228073,"score_gpt":0.34980055287719536,"score_spread":0.31302456064491463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895884786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770301,0.005034812,0.0038670634,0.002708665,0.0056404187,0.0017098027,0.000082107494,0.00025486544,0.0036721898],"genre_scores_gemma":[0.9909181,0.0027572454,0.00076823536,0.0043398463,0.0008543386,0.00020889494,0.00000835107,0.000053755684,0.00009124364],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981066,0.00017442473,0.00026737602,0.0006847258,0.00034946486,0.0004173895],"domain_scores_gemma":[0.9992045,0.00017743808,0.00008830959,0.00036196221,0.0000638979,0.0001038718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009280885,0.00024573068,0.00020582289,0.00016844958,0.00021643784,0.00004857576,0.00034046522,0.00004851216,0.000108036584],"category_scores_gemma":[0.00012683624,0.000223274,0.00011067231,0.0003028344,0.00017859241,0.00020475106,0.000057139918,0.00006798034,0.000083179475],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004960572,0.00048605245,0.00019939578,0.000027973418,0.0000069962393,0.0000071657773,0.0033376138,0.00022165026,0.8972808,0.0036645944,0.0015033537,0.09276834],"study_design_scores_gemma":[0.000985792,0.00044646324,0.0002030357,0.000036082623,0.0000011134986,0.0000014029401,0.00017777999,0.0011677226,0.76924676,0.00032833315,0.22716753,0.00023795576],"about_ca_topic_score_codex":0.0000037867412,"about_ca_topic_score_gemma":0.0000019159113,"teacher_disagreement_score":0.22566418,"about_ca_system_score_codex":0.00004469684,"about_ca_system_score_gemma":0.000045644396,"threshold_uncertainty_score":0.9104849},"labels":[],"label_agreement":null},{"id":"W2970900708","doi":"10.1080/21678707.2019.1651641","title":"Recent developments with defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome","year":2019,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Defibrotide; Medicine; Hepatic veno-occlusive disease; Transplantation; Disease; Chemotherapy; Intensive care medicine; Clinical trial; Hematopoietic stem cell transplantation; Surgery; Internal medicine","score_opus":0.018475461179970818,"score_gpt":0.28311162799908024,"score_spread":0.2646361668191094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970900708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914173,0.0016980934,0.00072425173,0.0012027482,0.0009413688,0.0035072258,0.00004191163,0.000057013403,0.0004100832],"genre_scores_gemma":[0.99207187,0.0043253424,0.0021846741,0.00020123579,0.0000943702,0.0004101087,0.00026168698,0.000051426065,0.00039930834],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99872017,0.000038949333,0.0003076313,0.00030717734,0.00040707368,0.00021900175],"domain_scores_gemma":[0.999017,0.00025487575,0.00014192106,0.0003438099,0.00011337993,0.00012900439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007377442,0.00021249824,0.00031739866,0.00008979747,0.000087439825,0.000011007112,0.000071836905,0.000052878742,0.00016009019],"category_scores_gemma":[0.000014265226,0.00013077493,0.00009136997,0.0001472105,0.000046129335,0.000055639426,0.000006444366,0.000042268828,0.00006680533],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059771284,0.011969629,0.24620527,0.0054829656,0.005620326,0.00025788634,0.13121635,0.0017086688,0.02453647,0.005109093,0.004042804,0.5040793],"study_design_scores_gemma":[0.046373602,0.019937502,0.41652557,0.008248786,0.00038639456,0.00088648696,0.008577267,0.0025538334,0.17978235,0.00023513068,0.31488067,0.001612397],"about_ca_topic_score_codex":0.000023743683,"about_ca_topic_score_gemma":0.0000016003925,"teacher_disagreement_score":0.50246686,"about_ca_system_score_codex":0.00027785113,"about_ca_system_score_gemma":0.00018809036,"threshold_uncertainty_score":0.5332847},"labels":[],"label_agreement":null},{"id":"W3019361312","doi":"10.1080/21678707.2020.1760837","title":"Advances in therapeutic treatment options for ANCA-associated vasculitis","year":2020,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Rituximab; Maintenance therapy; Intensive care medicine; Guideline; ANCA-Associated Vasculitis; Vasculitis; Cyclophosphamide; Expert opinion; Immunology; Internal medicine; Disease; Chemotherapy; Pathology; Lymphoma","score_opus":0.03436985990012032,"score_gpt":0.3269259203116747,"score_spread":0.2925560604115544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019361312","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12678923,0.38752005,0.012675017,0.39221933,0.008055695,0.01721917,0.0012749762,0.0027055102,0.051541045],"genre_scores_gemma":[0.9567425,0.037415713,0.0003676285,0.0033391488,0.00051080564,0.0006524404,0.00052709214,0.000048996728,0.00039567178],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988693,0.000055918445,0.00027086772,0.00034693768,0.00018029293,0.00027669762],"domain_scores_gemma":[0.9994223,0.0000953261,0.00006175215,0.0001801148,0.000055455403,0.00018506646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058924645,0.00018981959,0.00033151815,0.00009910058,0.00012657474,0.000017282633,0.00006518069,0.0001256631,0.00032645193],"category_scores_gemma":[0.00004569208,0.00014980049,0.00026560138,0.00028273708,0.00003980622,0.00010728427,0.000009661386,0.000115047704,0.00008534851],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016070106,0.0070156446,0.0030765173,0.0001721482,0.0018523675,0.00008490385,0.03854395,0.00089604425,0.0051932544,0.08706488,0.023465034,0.8310282],"study_design_scores_gemma":[0.02321294,0.0043282853,0.006099856,0.00051161286,0.00004946961,0.000015236992,0.003035498,0.002252877,0.0019439859,0.0013708613,0.9566781,0.0005012722],"about_ca_topic_score_codex":0.000030260344,"about_ca_topic_score_gemma":0.0000070187825,"teacher_disagreement_score":0.93321306,"about_ca_system_score_codex":0.00026773557,"about_ca_system_score_gemma":0.00008862374,"threshold_uncertainty_score":0.61086863},"labels":[],"label_agreement":null},{"id":"W4385458457","doi":"10.1080/21678707.2023.2241347","title":"Real world data for rare diseases research: The beginner’s guide to registries","year":2023,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Disease; Medical record; Rare disease; Summary of Product Characteristics; Disease registry; MEDLINE; Product (mathematics); Family medicine; Medical emergency; Data science; Drug; Pathology; Computer science; Pharmacology","score_opus":0.11066388381752931,"score_gpt":0.423275749054378,"score_spread":0.3126118652368487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385458457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6284873,0.026186265,0.0010272933,0.26977578,0.011873906,0.011353441,0.029024445,0.0010002641,0.021271307],"genre_scores_gemma":[0.8624,0.023506438,0.001234142,0.0076123187,0.01131117,0.0017444077,0.0370604,0.00030509086,0.054826066],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982635,0.00011658897,0.00020759807,0.00066643866,0.00029689661,0.00044898025],"domain_scores_gemma":[0.99775183,0.0001612002,0.000054037264,0.0016727633,0.00015012831,0.00021004325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004936312,0.00017138806,0.00014381162,0.0001428421,0.00042686993,0.00010474926,0.0010567529,0.00004906362,0.000019891577],"category_scores_gemma":[0.00056615553,0.00012496738,0.00009483442,0.0004090833,0.00017343096,0.000006408259,0.0007880355,0.0000713098,0.000085812164],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003194959,0.000051022438,0.0000923375,0.000009323975,0.000034538138,0.0000034983595,0.0001524767,0.000023306584,0.003331614,0.0009952538,0.98863864,0.0063484707],"study_design_scores_gemma":[0.00033965663,0.00020718048,0.0010270849,0.000031826126,0.000002331722,0.0000010521784,0.001305577,0.00006640352,0.0040374277,0.00013768407,0.99265903,0.0001847371],"about_ca_topic_score_codex":0.00016337696,"about_ca_topic_score_gemma":0.000095176,"teacher_disagreement_score":0.26216346,"about_ca_system_score_codex":0.000026765216,"about_ca_system_score_gemma":0.00019198144,"threshold_uncertainty_score":0.5096022},"labels":[],"label_agreement":null},{"id":"W4391470543","doi":"10.1080/21678707.2024.2313766","title":"Orphan drugs approved in Canada: health technology assessment, price negotiation, and government formulary listing","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Arthur B. McDonald-Canadian Astroparticle Physics Research Institute; Fraser Institute; Wilfrid Laurier University; Canadian Institute for Health Information","funders":"","keywords":"Formulary; Medicine; Orphan drug; Listing (finance); Government (linguistics); Negotiation; List price; Pharmacology; Bioinformatics; Business; Finance; Law; Political science","score_opus":0.12472499760889985,"score_gpt":0.40657598618659424,"score_spread":0.2818509885776944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391470543","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1965051,0.07628723,0.015381392,0.67905223,0.009880105,0.0049770074,0.0010273798,0.00063840265,0.016251152],"genre_scores_gemma":[0.9715785,0.0026206109,0.003079239,0.021229934,0.0005704832,0.00035287163,0.000098933495,0.00008177175,0.00038766832],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952122,0.0002158069,0.0028136123,0.000898485,0.00025023203,0.0006096658],"domain_scores_gemma":[0.99753505,0.00072628545,0.001014616,0.00046138334,0.000030712094,0.00023193797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0057989946,0.00029074808,0.00082938035,0.00042414057,0.00023427786,0.00012576143,0.00026492646,0.00014701959,0.00017423951],"category_scores_gemma":[0.0006400369,0.0003582407,0.000058327354,0.0004928976,0.000044988792,0.00044511072,0.000113405484,0.0003515258,0.00011479195],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004809505,0.0003601174,0.044728935,0.0015468082,0.00021426703,0.000010362749,0.022227168,0.0002554459,0.000030715295,0.70314354,0.19742104,0.030013526],"study_design_scores_gemma":[0.001903711,0.0002590921,0.01831425,0.0009953112,0.0000015496345,0.000015361135,0.027702192,0.06484756,0.000050035327,0.0055300966,0.87942064,0.0009602239],"about_ca_topic_score_codex":0.20140906,"about_ca_topic_score_gemma":0.041318174,"teacher_disagreement_score":0.7750734,"about_ca_system_score_codex":0.007263251,"about_ca_system_score_gemma":0.0017327748,"threshold_uncertainty_score":0.99988693},"labels":[],"label_agreement":null}]}